Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Dual endothelin angiotensin receptor antagonists
4 evidence topics · 3 sources
Sparsentan indication, dosing, and REMS
Sparsentan versus irbesartan in FSGS: DUPLEX results in the label
Sparsentan versus irbesartan in FSGS: DUPLEX primary publication
“At 36 weeks, the percentage of patients with partial remission of proteinuria was 42.0% in the sparsentan group and 26.0% in the irbesartan group (P = 0.009), a response that was sustained through 108 weeks.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Among patients with FSGS, there were no significant between-group differences in eGFR slope at 108 weeks, despite a greater reduction in proteinuria with sparsentan than with irbesartan.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Sparsentan in participants with APOL1 high-risk genotypes: DUPLEX post hoc analysis
“Finally, 14 patients (4%) had two APOL1 high-risk alleles, nine in the sparsentan and five in the irbesartan groups.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Sparsentan treatment resulted in profound (approximately 50%) sustained reduction of UPCR in the patients with APOL1 high-risk genotypes, although the treatment effect versus irbesartan was not sustained during the second year of the treatment period (Figure 1C).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“CR occurred exclusively in sparsentan-treated patients among those with podocyte gene variants (8% versus 0%), in 18% versus 7% of patients with COL4A3–5 gene variants, and in 33% versus 20% of patients with APOL1 high-risk genotypes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Owing to the small sample size in each genetic subgroup, the result has limited analytic power” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Subgroup | Sparsentan, time-averaged change from baseline in UPCR, % (95% CI) | Irbesartan, time-averaged change from baseline in UPCR, % (95% CI) | Relative change, % (95% CI) | P value |
|---|---|---|---|---|
| APOL1 high-risk genotypes | “−54.3 (−76.6 to −10.9)”View highlighted excerpt for this quote | “−33.8 (−71.2 to 52.2)”View highlighted excerpt for this quote | “−27.3 (−78.1 to 141.2)”View highlighted excerpt for this quote | “0.57”View highlighted excerpt for this quote |